Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Licarbazepine · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| licarbazepine | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Licarbazepine | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. written informed consent provided prior to participation in the extension study 2. successful completion of study CLIC477D2301 3. willingness and ability to comply with all study requirements Exclusion Criteria: 1. premature discontinuation from study CLIC477D2301 2. failur...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Licarbazepine is an investigational small molecule developed for the treatment of bipolar disorder, specifically manic episodes of Bipolar I Disorder. It has been studied in Phase 3 clinical trials in adults aged 18 years and older. It is not approved for any indication.
Licarbazepine is being developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 3 clinical program evaluating the drug in bipolar disorder.
Licarbazepine is in Phase 3 clinical development. All four trials identified are Phase 3 studies, and all have been completed. The drug remains investigational and has not been approved by the FDA for any indication.
Licarbazepine has been evaluated in four completed Phase 3 trials: NCT00238485, NCT00228059, NCT00107939, and NCT00107926. These studies enrolled a total of 1,179 participants and assessed Licarbazepine in manic episodes of Bipolar I Disorder or Bipolar Disorder.
Licarbazepine is a small molecule. No molecular target or target class is specified for Licarbazepine in the available information, so its precise mechanism of action cannot be described here.